SUBSCRIBE
SUBSCRIBE
News   Deals

Daiichi Sankyo Co Ltd. Says Offer for Ranbaxy Laboratories Oversubscribed

September 24, 2008 | 
1 min read
TOKYO, Sept 24 (Reuters) - Japan's third-largest drugmaker Daiichi Sankyo Co said on Wednesday its open offer to buy up to 20 percent of India's generic drugmaker Ranbaxy Laboratories Ltd was oversubscribed.
Mergers & acquisitions Asia
Daiichi Sankyo
MORE ON THIS TOPIC
Blank paper notes attached by adhesive tape, white background, vector eps10 illustration
Deals
Ipsen sends clear Memo to rare diseases with up to $796M buyout
July 1, 2026
 · 
2 min read
 · 
Gabrielle Masson
Podcast
Sentiment at BIO soars as FDA resets, dealmaking evolves; Amgen’s Tavneos in hot water
July 1, 2026
 · 
2 min read
 · 
Jef Akst
Upward arrow on the background of the flag of China. Paper plane. Economic recovery. Copy space. Business. Background.
China
Deerfield bets up to $1.6B to snag autoimmune asset in China for Boulevard
June 30, 2026
 · 
1 min read
 · 
Annalee Armstrong
Solution Concept with Handshake on Chalkboard Background
Mergers & acquisitions
Zymeworks adds lung disease drug, royalty deals in nearly $1B pick up of Theravance
June 29, 2026
 · 
2 min read
 · 
Annalee Armstrong